Nasdaq:US$34.13 (+0.27) | HKEX:HK$55.55 (+0.55) | AIM:£5.14 (+0)
News & Presentations
Previous Article   |   Next Article
Announcements & Press Releases, Regulatory Notice | 29 Oct 2021

Total Voting Rights

Hong Kong, Shanghai, & Florham Park, NJ Friday, October 29, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at October 29, 2021, the issued share capital of HUTCHMED consisted of 864,442,280 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

 

The above figure of 864,442,280 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

 

For illustrative purposes only, the 864,442,280 ordinary shares would be equivalent to 864,442,280 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 172,888,456 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,500 personnel across all its companies, at the center of which is a team of over 1,400 in oncology/immunology.  Since inception it has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries

Mark Lee,
Senior Vice President
+852 2121 8200
Annie Cheng,
Vice President
+1 (973) 567 3786

Media Enquiries

Americas
Brad Miles,
Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe
Ben Atwell / Alex Shaw,
FTI Consulting
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia
Zhou Yi,
Brunswick
+852 9783 6894 (Mobile)
HUTCHMED@brunswickgroup.com

Nominated Advisor

Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited +44 (20) 7886 2500